HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company specializing in cardiac detection and monitoring, announced the closing of its underwritten public offering of 12.5 million shares of common stock, generating gross proceeds of $10 million before expenses. The transaction, completed on April 16, 2026, was supported by key stakeholders including ClearCardio(TM), company leadership, and institutional investors.
The funds will be used to accelerate the commercialization of HeartBeam’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities, and general corporate purposes. The company’s platform technology is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG, enabling portable devices that can be used wherever the patient is located.
HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to its technology. According to the press release, the offering will support the company’s mission to redefine cardiac health management by allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities.
The full press release is available at https://ibn.fm/9iNYY. More information about HeartBeam is available on the company’s website, and the latest news and updates relating to BEAT can be found in the company’s newsroom at https://ibn.fm/BEAT.
The closing of this offering marks a significant step for HeartBeam as it seeks to commercialize its innovative cardiac monitoring technology, which has the potential to improve early detection and management of heart conditions. With the additional capital, the company is positioned to expand its product pipeline and enhance its AI-driven analytics, aiming to provide actionable heart intelligence to physicians and patients alike.
